Skip to main content
Caplight Logo









Exogenus Therapeutics

Exogenus Therapeutics

Private
CantanhedeHealthcare & Life Scienceshttps://www.exogenus-t.com/

Last Round

Strategic

Apr 24, 2024

Total Funding Raised

$1.32M

Company Overview

Exogenus Therapeutics is a biotechnology company developing an exosome-based platform technology designed to offer a pipeline of therapeutic products for skin and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts, Revenue Share

AI Layer

Non-AI

Keywords

extracellular vesiclesexosomesregenerative medicineexosome therapycell-free therapybiotechnologyumbilical cord bloodbiologicsimmunomodulationtissue regenerationanti-inflammatory therapychronic wound healingfibrotic diseasesosteoarthritispre-clinical developmentGMP manufacturing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Exogenus Therapeutics Comparables

Compare Exogenus Therapeutics with similar companies based on industry and business-model similarity.

Exogenus Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Lysatpharma GmbH
84%
ConvEyXO
83%
RION
82%

Exogenus Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicApr 24, 2024
GrantNov 9, 2022
GrantDec 30, 2019
SeedDec 10, 2015
Pre SeedAug 1, 2015

Exogenus Therapeutics Investors

Notable investors and investment history

Exogenus Therapeutics investors
InvestorRounds
European Union's Horizon Research and Innovation programGrant
3xP GlobalStrategic
COHiTEC ProgramAccelerator
Criteria Capital RiscPre Seed, Seed
Blue Bio ValueGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 15, 2026

    Monthly visitors increased 1680% from 15 to 267.

  • Dec 5, 2024

    Grew 40% QoQ from 10 to 14 employees.

Recent news

Latest coverage and updates

  • attends_eventSep 15, 2026

    Exogenus Therapeutics attended event European Lifestars Awards 2026 on Sep 15th '26.

  • recognized_asSep 15, 2026

    Exogenus Therapeutics recognized as finalist at European Lifestars Awards 2026 on Sep 15th '26.

  • recognized_asSep 15, 2026

    Joana Simões Correia at Exogenus Therapeutics recognized as finalist in the Women-Led Business of the Year category at European Lifestars Awards 2026 on Sep 15th '26.

Exogenus Therapeutics Filings

Explore SEC and related filing metadata, where available.

Exogenus Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Exogenus Therapeutics's valuation, stock price, and market status.

Is Exogenus Therapeutics a public or private company?

Exogenus Therapeutics is a private company.

What is the current stock price of Exogenus Therapeutics?

Exogenus Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Exogenus Therapeutics worth (valuation)?

Valuation information for Exogenus Therapeutics is not publicly available.

Can I buy Exogenus Therapeutics stock?

Exogenus Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Exogenus Therapeutics's last funding round?

Exogenus Therapeutics's most recent funding round was Strategic on April 24, 2024.

Who are the main investors in Exogenus Therapeutics?

Key investors in Exogenus Therapeutics include 3xP Global, Caixa Capital Risc.

Will Exogenus Therapeutics IPO soon?

No public IPO plans have been announced for Exogenus Therapeutics.

How can I track Exogenus Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Exogenus Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCantanhede
Employee Range10
Year Founded2015
Last FundingApr 24, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?